PMV Pharmaceuticals, Inc.
rezatapopt
platinum-resistant/refractory ovarian cancer
Resolved
86days ago
Phase 1 readout · Apr 12, 2026
What's at stake
Phase 1 trial results for rezatapopt in platinum-resistant/refractory ovarian cancer are due Apr 12, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Phase 1 results from the ongoing Phase 1/2 PYNNACLE study were published in the New England Journal of Medicine, “Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.””